Analyst Serge Belanger from Needham maintained a Buy rating on Esperion (ESPR – Research Report) and decreased the price target to $5.00 from $6.00.
Serge Belanger has given his Buy rating due to a combination of factors, including Esperion’s strong financial performance and strategic initiatives. The company’s fourth-quarter revenue exceeded expectations, largely driven by a significant milestone payment from Otsuka, which contributed to the overall positive financial results. Although there was a slight miss in U.S. sales for Nexletol/Nexlizet, the year-over-year growth remains impressive, indicating a robust demand for the products.
Looking ahead, Esperion is focusing on executing its sales strategy, which is expected to drive further growth in 2025. The company’s efforts to expand its product pipeline with innovative combinations, such as the triple combo product anticipated in 2027, demonstrate a commitment to long-term growth. Additionally, Esperion’s business development plans to introduce a new commercial product further support the positive outlook, justifying the Buy rating despite a minor adjustment in the price target.
According to TipRanks, Belanger is an analyst with an average return of -0.4% and a 39.96% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Revance Therapeutics, Viridian Therapeutics, and NewAmsterdam Pharma Company.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $16.00 price target.